{"news_desk": "National", "print_page": "12", "section_name": "U.S.", "subsection_name": null, "byline": {"contributor": "", "original": "By ROBERT PEAR", "person": [{"rank": 1, "role": "reported", "firstname": "Robert", "organization": "", "lastname": "PEAR"}]}, "abstract": "Medicare has decided that it will pay for anticancer drug Blincyto, made by Amgen, recognition of high cost and unique value of drug for patients suffering from specific form of leukemia; Obama administration had initially indicated Medicare would not pay for drug, but reversed its decision, according to text of final rule to be published; decision comes at time when health providers have raised concerns about high costs of new cancer treatments.", "type_of_material": "News", "word_count": "915", "lead_paragraph": "The Obama administration has decided that Medicare will pay for one of the newest, most expensive cancer medications, Blincyto, which costs about $178,000 and treats an aggressive form of leukemia.", "pub_date": "2015-08-09T00:00:00Z", "document_type": "article", "slideshow_credits": null, "headline": {"main": "Medicare, Reversing Itself, Will Pay More for an Expensive New Cancer Drug", "print_headline": "Medicare, Reversing Itself, Will Pay More for an Expensive New Cancer Drug"}, "snippet": "The Obama administration has decided that Medicare will pay for one of the newest, most expensive cancer medications, Blincyto, which costs about $178,000 and treats an aggressive form of leukemia.", "multimedia": [{"height": 126, "url": "images/2015/08/09/us/09medicare/09medicare-thumbWide.jpg", "legacy": {"widewidth": "190", "wideheight": "126", "wide": "images/2015/08/09/us/09medicare/09medicare-thumbWide.jpg"}, "type": "image", "width": 190, "subtype": "wide"}, {"height": 476, "url": "images/2015/08/09/us/09medicare/09medicare-articleLarge.jpg", "legacy": {"xlargewidth": "600", "xlargeheight": "476", "xlarge": "images/2015/08/09/us/09medicare/09medicare-articleLarge.jpg"}, "type": "image", "width": 600, "subtype": "xlarge"}, {"height": 75, "url": "images/2015/08/09/us/09medicare/09medicare-thumbStandard.jpg", "legacy": {"thumbnailwidth": "75", "thumbnail": "images/2015/08/09/us/09medicare/09medicare-thumbStandard.jpg", "thumbnailheight": "75"}, "type": "image", "width": 75, "subtype": "thumbnail"}], "web_url": "http://www.nytimes.com/2015/08/09/us/medicare-reversing-itself-will-pay-more-for-an-expensive-new-cancer-drug.html", "keywords": [{"rank": "1", "is_major": "Y", "value": "Medicare", "name": "subject"}, {"rank": "2", "is_major": "Y", "value": "Drugs (Pharmaceuticals)", "name": "subject"}, {"rank": "3", "is_major": "Y", "value": "Cancer", "name": "subject"}, {"rank": "4", "is_major": "N", "value": "Leukemia", "name": "subject"}, {"rank": "5", "is_major": "N", "value": "Blincyto (Drug)", "name": "subject"}, {"rank": "6", "is_major": "N", "value": "Amgen Inc", "name": "organizations"}, {"rank": "7", "is_major": "N", "value": "Food and Drug Administration", "name": "organizations"}], "blog": [], "_id": "55c6873a38f0d870ed943303", "source": "The New York Times"}